Robert Elfont

    Robert Elfont MD, PhD
    Chief Medical Officer

    Robert Elfont, MD, PhD, is Aimmune’s Chief Medical Officer. Dr. Elfont founded the specialty consulting firm, Strategic Clinical Development, LLC, in 2009. He has served as CMO for several biotech companies including PhotoThera and Avigen. Before moving to the biotech sector, Dr. Elfont held senior medical director positions at Roche, Pfizer and Teva Neuroscience. While at Teva, Dr. Elfont worked in the field of orally induced immune tolerance. Dr. Elfont was also an assistant professor of neurology at Johns Hopkins University School of Medicine and Drexel University College of Medicine. - See more at: http://www.aimmune.com/about/team/#sthash.ifEAHcko.dpuf

    His research activities focused on immune cell trafficking. Dr. Elfont completed a neurology residency and fellowship in neuroimmunology and neurovirology at Johns Hopkins. He earned his MD and PhD from the University of Rochester and received additional post-graduate training at the University of Cambridge.

    Stephen Dilly

      Stephen G Dilly MBBS, PhD
      Chief Executive Officer

      Stephen G. Dilly, MBBS, PhD, is Aimmune’s Chief Executive Officer and a member of Aimmune’s Board of Directors. He was formerly the CEO at APT Pharmaceuticals. Dr. Dilly was previously Senior Vice President, Head of Development, and Chief Medical Officer at Chiron BioPharmaceuticals. Before that, he held a number of senior executive clinical, development and commercial support positions at companies including SmithKline Beecham and Genentech.

      Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.

      Howard Raff

        Howard Raff PhD
        Chief Operating Officer

        Howard Raff, PhD, is Aimmune’s Chief Operating Officer. Previously, Dr. Raff was COO at APT Pharmaceuticals and Head of West Coast Operations for The Biologics Consulting Group. He also held executive positions at Chiron Corporation, including Vice President, Development Management, which entailed responsibility for development of the biopharmaceutical portfolio. Dr. Raff spent 11 years in discovery, research and development for Genetic Systems and Bristol-Myers Squibb.

        He has had significant involvement with more than 50 investigational projects, of which several have become marketed pharmaceutical products in the United States and Europe. Early in his career, Dr. Raff was an adjunct associate professor at the University of Washington Medical School. He also served a post-doctoral fellowship for the Howard Hughes Medical Institute at the University of California, San Francisco. Dr. Raff obtained MS and PhD degrees in Immunology and Microbiology from Washington State University.